<scp>Anti‐IL23</scp>
            for nail psoriasis in real life: Results of efficacy and safety during a 52‐week period

Trovato, Emanuele; Cortonesi, Giulio; Orsini, Corinne; Capalbo, Eugenio; Cinotti, Élisa; Rubegni, Pietro; Cartocci, Alessandra

doi:10.1111/dth.15506

Cited by 7 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Investigating the long-term impact of bimekizumab on genital symptoms and sexual activity is crucial, as the effects of treatment on sexual activity within a relationship may take longer to become evident in some cases. The involvement of difficult-to-treat areas can severely impact the patients quality of life and, in this context, both anti-IL-23 and anti-IL-17 drugs have shown promising data [ 45 , 46 ]. The role of bimekizumab in this setting has not been explored yet, thus our study provides initial real-world data, even though they are limited by a small sample size and a relatively short observation period.…”

Section: Discussionmentioning

confidence: 99%

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Orsini,

Malagoli,

Balato

et al. 2024

Dermatology Practical &Amp; Conceptual

View full text Add to dashboard Cite

Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis, their efficacy in challenging-to-treat areas remains inadequately explored. Intriguingly, studies have shown that interleukin (IL)-17 inhibitors exhibit effectiveness in addressing genital psoriasis. Objectives: We aimed to determine the effectiveness profile of bimekizumab in patients affected by moderate-to-severe plaque psoriasis with involvement of genitalia. Methods: Bimekizumab, a dual inhibitor of both IL-17A and IL-17F, was the focus of our 16-week study, demonstrating highly favorable outcomes for patients with genital psoriasis. The effectiveness of bimekizumab was evaluated in terms of improvement in Static Physician's Global Assessment of Genitalia (sPGA-G) and Psoriasis Area and Severity Index. Results: Sixty-five adult patients were enrolled. Remarkably, 98.4% of our participants achieved a clear sPGA-G score (s-PGA-g=0) within 16 weeks. Moreover, consistent improvements were observed in PASI scores, accompanied by a significant reduction in the mean Dermatology Life Quality Index (DLQI), signifying enhanced quality of life. Notably, none of the patients reported a severe impairment in their quality of life after 16 weeks of treatment. In our cohort of 65 patients, subgroup analyses unveiled that the effectiveness of bimekizumab remained unaffected by prior exposure to other biologics or by obesity. Conclusions: Our initial findings suggest that bimekizumab may serve as a valuable treatment option for genital psoriasis. Nevertheless, further research with larger sample sizes and longer-term follow-up is imperative to conclusively validate these results.

show abstract

Section: Discussionmentioning

confidence: 99%

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Orsini,

Malagoli,

Balato

et al. 2024

Dermatology Practical &Amp; Conceptual

View full text Add to dashboard Cite

show abstract

“…Beyond skin lesions, psoriasis also affects multiple organs or systems such as cardiovascular diseases or metabolic diseases, in which RBP-4 plays vital roles ( 6 , 25 ). The management of psoriasis has experienced rapid development in recent years, with numerous monoclonal antibodies being applied ( 26 , 27 ), and better efficacy can be obtained. Furthermore, in the management of psoriasis, the management of comorbidities cannot be ignored.…”

Section: Discussionmentioning

confidence: 99%

Association between retinol binding protein-4 and psoriasis vulgaris: a systematic review and meta-analysis

Gao,

Cui,

Cheng

2023

Front. Med.

View full text Add to dashboard Cite

BackgroundPsoriasis vulgaris is a chronic skin disease which is related to cardiovascular and metabolic diseases. In the pathogenesis of these diseases, adipokines, including retinol binding protein-4 (RBP-4), play crucial roles. Studies have also shown that RBP-4 might be a meaningful factor in psoriasis however, relying on the analysis of a single study have some drawbacks.ObjectiveTo evaluate the association between RBP-4 and psoriasis vulgaris more comprehensively.MethodsSix databases were searched to obtain relevant publications. The selection of the included studies was based on a criteria. The standardized mean difference (SMD) was used for analysis. A value of p < 0.05 was defined as significance.ResultsSeven studies were included, with 271 cases and 235 controls. In the comparison between patients and controls, the merged data suggested that levels of RBP-4 were significantly higher in patients (SMD = 0.61, 95%CI: 0.14, 1.07, p < 0.05). In five studies containing the data of RBP-4 levels before and after treatment, no significance was found, either for RBP-4 levels in the after-treatment group and control group in these five studies (p > 0.05). Subgroup analysis was conducted based on the therapy method. Patients with systematic treatment showed a significant decrease of BRP-4 level after the treatment (SMD = −0.64, 95%CI: −1.26, −0.03, p < 0.05).ConclusionFor patients with psoriasis vulgaris, RBP-4 levels are elevated, and systematic treatment can lower these levels. RBP-4 might act as a key indicator for the diagnosis, efficacy assessment, and comorbidity monitoring of the patients. Further studies with well-designed protocols and enlarged populations are still needed.

show abstract

“… 5 Several authors have already reported their experiences in real-world clinical practice, confirming its short-term and long-term effectiveness in plaque psoriasis. 6 , 7 Some data have also been reported about its effectiveness in difficult-to-treat areas, such as nails and scalp 8 , 9 but few data are available regarding its use for PP. 9 – 13 …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

Caldarola¹,

Zangrilli²,

Palmisano³

et al. 2023

DIC

View full text Add to dashboard Cite

Background Data on the treatment of palmoplantar psoriasis (PP) are scarce, representing a therapeutic challenge. This study aims to assess the efficacy and safety of risankizumab in a population of patients with psoriasis with a palmoplantar involvement, over a 52-week treatment period. Methods We performed a retrospective analysis in a cohort of patients with PP, with or without involvement of other skin sites. Palmoplantar Psoriasis Area and Severity Index (ppPASI) was assessed at baseline and after 4, 16, 28 and 52 weeks, to evaluate the PP severity. Results Sixteen patients were enrolled. The rates of ppPASI90 responses constantly increased during the period of observation and were 18.7%, 62.2%, 75.0% and 81.2% at weeks 4, 16, 28 and 52, respectively. Only two patients suspended treatment because of ineffectiveness at week 16. Conclusion Our data from a series of 16 patients reveal that risankizumab could represent an effective and safe therapeutic choice in patients with PP.

show abstract

Anti‐IL23 for nail psoriasis in real life: Results of efficacy and safety during a 52‐week period

Cited by 7 publications

References 16 publications

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)

Association between retinol binding protein-4 and psoriasis vulgaris: a systematic review and meta-analysis

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

Contact Info

Product

Resources

About